Mangoceuticals Inc. (MGRX)
MGRX trades on Nasdaq in Health Care, Misc Health and Biotechnology Services. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1938046/000149315226014478/0001493152-26-014478-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MGRX on Nasdaq |
| Sector | Health Care |
| Industry | Misc Health and Biotechnology Services |
| Country | United States |
| IPO year | 2023 |
| SEC CIK | 0001938046 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $456K |
| Net income | -$20.6M |
| Operating income | -$18.0M |
| Net margin | -4526.8% |
| Operating margin | -3954.3% |
| Revenue growth | -26.0% |
| Cash | $1.5M |
| Total assets | $16.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 7.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about the ability of the Company to continue as a going concern." | 10-Q 2026-08-13 |
| Cash and burn | $229K cash; operating cash flow -$973K a quarter. | Report 2026-06-30 |
| Shares outstanding | 21,567,422 (2026-08-13); 10,535,791 a year earlier; 16,714,500 three years earlier. 3y figure adjusted for split (1-for-15 overall). | Cover page 2026-08-13 |
| Reverse splits, 3 years | 1; latest 1-for-15 on 2024-10-16 | Source 2024-10-16 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-10-09 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-02-06 |
| Auditor | Turner, Stone & Company, L.L.P., Dallas, Texas, United States | PCAOB Form AP 2026-04-14 |
| Late filings, 12 months | 2 NT notices | NT 10-Q 2026-05-15 |
| Insider trades, 12 months | Bought $0, sold $174K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $69K | -$1.3M | -$261K | $229K | $45K | $315K | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $68K | -$3.4M | -$1.3M | $175K | No debt tags | $415K | 10-Q 2026-05-19 |
| Q4 2025 2025-12-31 | $94K | -$2.8M | -$1.1M | $1.5M | No debt tags | $456K | 10-K 2026-04-01 |
| Q3 2025 2025-09-30 | $84K | -$7.6M | -$1.2M | $481K | No debt tags | $467K | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $168K | -$5.4M | -$1.3M | $101K | No debt tags | $516K | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $109K | -$4.8M | -$2.3M | $76K | $0 | $511K | 10-Q 2026-05-19 |
| Q4 2024 2024-12-31 | $105K | -$1.9M | -$1.1M | $59K | $150K | $616K | 10-K 2026-04-01 |
| Q3 2024 2024-09-30 | $133K | -$2.0M | -$1.2M | $74K | $0 | $755K | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | -20.5% |
| 1 month | -58.3% |
| 3 months | -70.9% |
| Year to date | -79.1% |
| 1 year | -87.0% |
| From 52-week high | -89.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Misc Health and Biotechnology Services
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NIVF | NewGenIvf Group Limited | $0.2050 | -11.33% | $2.0M |
| CCEL | Cryo-Cell International Inc. | $4.55 | -6.19% | $36.7M |
| PARK | Park Dental Partners Inc. | $19.72 | -8.24% | $109.2M |
| VMD | Viemed Healthcare Inc. Common Shares | $9.15 | -0.22% | $346.7M |
| AGL | agilon health inc. | $116.75 | +0.94% | $2.0B |
| PGNY | Progyny Inc. | $37.15 | +2.68% | $2.7B |
| SHC | Sotera Health Company | $16.25 | -2.17% | $4.6B |
| DVA | DaVita Inc. | $174.22 | -0.19% | $11.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier